NYSE MKT: NSPR

April 2016

Forward Looking Statements

This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

An emerging medical device company developing and commercializing advanced technology for interventional cardiology and other vascular procedures

NYSE MKT: **NSPR**

Stock Price (3/30/16):	$0.52
52 Week Range:	$0.39-$4.20
Average Volume:	44K
Shares Outstanding (3/30/16):	10.7 M
Market Capitalization (3/30/16):	$5.57 M
Analyst Coverage:	H.C. Wainwright: Yi Chen Dawson James: Robert Wasserman Empire Asset Management: Cathy Reese
Total Cash (12/31/15):	$3.3 M
US Headquarters:	Boston, MA
International Headquarters:	Tel Aviv, Israel
# of Employees (3/30/2016):	37

Investment Highlights

Effectively Executing a "Neck Up" Interventional Strategy

- 2016 return to revenue growth driven by the full launch of carotid platform through strategic distribution partnerships, including with Penumbra, Inc.
- Operating and financial realignment inline with development and growth initiatives.
- Advancing into highly valued Neuro and Peripheral markets to leverage MicroNet technology into high growth segments.
- Pursuing collaboration activities on multiple MicroNet technology applications.


THE WALL STREET JOURNAL. ≡ U.S.
105
32
U.S. NEWS
Stents Boost Stroke Recovery, Study Finds
Using Devices to Pull Clots From Brain Arteries Can Help Patients
By THOMAS M. BURTON
Using a device to extract blood clots from brain arteries can significantly improve patients' ability to rebound from a stroke, according to a landmark study published Wednesday.


The New York Times
Times Essentials
Search All NYTimes.com
Capital One
WORLD U.S. N.Y. / REGION BUSINESS TECHNOLOGY SCIENCE HEALTH SPORTS OPINION ARTS STYLE TRAVEL JOBS REAL ESTATE AUTOS
Search Health
Inside Health
Research Fitness & Nutrition Money & Policy Views Health Guide
The IBM Cloud is the cloud for business.
Made with IBM
Tap into the IBM Cloud. Learn more
REPORTER'S FILE
Precious Hours, Then Lives, Lost in Stroke's Wake
Well
Genes Tell Only Part of the Story
When Grief Won't Relent
Not Your Bubbe's Kasha
Ask Well: Put on the Snowshoes
Think Like a Doctor: Swept Off Her Feet Solved
The IBM Cloud


TIME
BUSH'S MILITARY RECORDS IS DISNEY MOUSETRAPPED?
THE SECRET KILLER
The surprising link between INFLAMMATION and HEART ATTACKS, CANCER, ALZHEIMER'S and other diseases
What you can do to fight it

Leadership: Significant Track Records of Success

EXECUTIVE TEAM

Alan Milinazzo, President, CEO & Director
- Medtronic
- Boston Scientific

Craig Shore, CFO
- Pfizer
- General Electric

Dr. James Barry, COO
- Boston Scientific
- Howmedica Division of Pfizer

Eli Bar, CTO
- Nicast

Gwen Bame, VP Corporate Development
- Boston Scientific
- Covidien

David Blossom, VP Global Marketing & Strategy
- Boston Scientific
- Covidien

BOARD OF DIRECTORS

Dr. Sol Barer, Chairman
- Former Chairman and CEO, Celgene

Isaac Blech, Vice Chairman
- Private financier in the life science industries

Alan Milinazzo, President, CEO & Director
- Medtronic
- Boston Scientific

Dr. James Barry
- SVP Corporate Technology Development at Boston Scientific
- Howmedica Division of Pfizer

Michael Berman
- Pres. Boston Scientific/Scimed
- Founder, Velocimed and Lutonix

James Loughlin
- KPMG
- Celgene Audit Chair

Paul Stuka
- Founder, Osiris
- Fidelity Management and Research

Dr. Campbell Rogers
- CMO, Heartflow
- CSO, Cordis/JNJ
- Associate Professor, Harvard School of Medicine

InspireMD

Technology: MicroNet™

Proprietary MicroNet Mesh for Embolic Prevention and Flow Diversion

MicroNet Platform

Ultra thin PET enhances clinical benefit of scaffold devices

- Provides revascularization benefit
- MicroNet acts as safety net by offering greater surface area coverage to prevent large debris flow
- Mesh configuration allows perfusion to vessel wall
- Made of a single fiber from a biocompatible polymer, widely used in medical implantations





Large Addressable Markets

Expanding the MicroNet™ Platform



MGuard™
- ✓ *$1.7B Market*
- ✓ CE Mark Cleared
- ✓ Coronary AMI, SVG



CGuard™
- ✓ *$500M Market**
- ✓ CE Mark Cleared
- ✓ Carotid



NVGuard
- ✓ *$125M Flow Diversion Market*
- ✓ *$550M Aneurysm Market*
- ✓ 2016E CE Mark Planned Submission for Flow Diverter
- ✓ Neurovascular

PVGuard
- ✓ *$1.7B Market*
- ✓ 2017E CE Mark Planned Submission
- ✓ Peripheral

*Source: JMP Securities, 2014

Carotid Market Opportunity

An Enhanced Minimally Invasive Solution

- Current standard of care: Open surgery: Carotid EndArterectomy (CEA)
- Current stents have not improved on CEA stroke rates (CREST) Mesh category is next generation technology.
- CGuard leads this emerging category
- CARENET and PARADIGM CGuard studies demonstrate superior outcomes to current technology.
- Immediate commercial opportunity with new Strategic Partner Penumbra

Carotid Solution

Emerging Market Opportunity

CGuard™ Embolic Prevention System

Combines stent and embolic protection in a single device



- CE marked
- Self-expanding nitinol stent
- Global market valued at $500M*
- Strong CARENET FIM data released 9/14 and 1/15
- Impressive all-comer data from PARADIGM presented 5/15
- Full launch now underway

*Source: JMP Securities, 2014

Positive CGuard™ Clinical Experience

CARENET (CARotid Embolic protection using microNET) FIM* Clinical Trial

- 30 Patient Safety and Efficacy clinical trial
- Prospective, multi-center, multispecialty, non-randomized single arm study
- DWMRI follow ups at 48hrs and 30 days for “gold-standard” neurological analysis

CARENET Highlights: 30 day Results

- Achieved primary end point
- 100% procedural success
- Zero MACCE at 30 days
- 50% fewer new ischemic lesions compared to historical non-mesh carotid artery stenting data
- Average lesion volume per patient 10 times smaller compared to historical non-mesh carotid artery stenting data

CARENET Highlights: 6 mo Results

- 3.6% MACCE rate at 6 months (Comparative data 8.09%)
- 6 month ultrasound analysis was indicative of healthy healing without restenosis concern with patent external and internal carotid arteries

CARENET Highlights: 12 mo Results

- Zero strokes or stoke related deaths
- 12 month ultrasound analysis confirmed no sign of vessel narrowing between 6 and 12 months confirming no restenosis concern

** FIM , First in Man*

Positive CGuard™ Clinical Experience

PARADIGM (Prospective evaluation of All-comer perRcutaneous cArotiD revascularization In symptomatic and increased-risk asymptomatic carotid artery stenosis using CGuard™ Mesh-covered embolic prevention system) Physician Initiated All-Comers Study

- Objective: To evaluate feasibility and outcome of routine anti-embolic stent system in unselected, consecutive carotid patients (all-comers)
- Investigator-independent neurological and angiographic evaluation
- 71 CGuard devices placed in 68 pts
- Device success: 100%; Procedure success: 100%
- MACCE (Death/stroke/MI) @ 48 hr: 0% @ 30 day: 0%
- Conclusions:
  - "> 90% all-comer carotid artery stenosis pts, including >50% symptomatic pts, can be treated using CGuard."

** FIM , First in Man*

Strategic Distribution Partnership

Rationale: Predictable, Sustainable & Profitable Revenue Growth

Penumbra

- Founded in 2005 as a Neurovascular company with a clinically-driven product development strategy. Very successful IPO in September.
- Reputation as the innovation leader in the neurovascular field
- Extending success beyond stroke into the periphery and neurosurgical markets
- Track record of consistent, profitable growth
- Management team with decades of vascular experience
- Entering carotid market to complement their stroke portfolio

Commercial Profile

Revenue Growth Driven by CGuard™ RX



Penumbra

- Late September 2015: Initiated Total Systems Solution Launch
- Key European Territories Targeted
- Opportunity to Increase Number of Target Territories

Note: Revenue in $000

Robust Pipeline

Expanding Indications with MicroNet™



Commercial

- CE Mark Cleared
- 12-month MASTER I, II

Commercial

- CE Mark Cleared
- CARENET Trial
- PARADIGM all-comer study
- CGuard FDA IDE protocol in draft form
- Penumbra Strategic Partnership

Exploring Market Opportunity

Exploring Market Opportunities:

- Flow Diverter
- Intra-Cranial Stent

2016E CE Mark Planned Submission for Flow Diverter

2017E CE Mark Planned Submission

CE Mark Planned Submission, Subject to Strategic Partner Support

**Planning & Development Phase*

Neurovascular Market Opportunity

Innovation Leads Growth

Flow Diversion For Unruptured Brain Aneurysms

Next Generation Combination Technology

- Current designs have sub-optimal trackability and in vessel flexibility: metal on metal devices
- MicroNet has proven flow diversion effect with ultra low profile and improves device flexiblity to improve device deliverability



2014 Competitive Landscape: Relatively Fewer Players with Limited Innovation		
Product	*Company*	*Approval*
Pipeline	Medtronic/Covidien	CE Mark / FDA 2011
Surpass	Stryker	CE Mark 2011
Silk	Balt Extrusion	CE Mark 2008

Source: MRG Neuro Report, Ev3 Revenue Data

NVGuard™ Neurovascular

Differentiation Yields Increased Utility

Our Significant Advantage Over Existing Flow Diverters

- MicroNet aperture & size
- Low metal to artery ratio
- Can be placed in side branches and bifurcations, which is impossible with current technology

Total Aneurysm Market Value: $946M

- Aneurysm Therapy (all types): $550M
- Aneurysms account for 74% of neuroendovascular disease states
- Estimated that flow diverters can treat 25% of all aneurysms
- Wide-neck Aneurysm Procedures: $350M
- Non-coil neurovascular products: estimated 12% CAGR from 2010-2016

Advanced neurovascular technologies are highly valued as the market segment expands with improved device performance



Source: MRG

Neurovascular Market

High Strategic interest with attractive valuations

- Medtronic acquires Medina Medical for $150 million
- Stryker Acquires Surpass Medical for $135 million
- Covidien Acquires Chestnut Medical for $150 million *
- Medtronic Acquires Lazarus Effect for $100 million

*

Intellectual Property Portfolio

PATENT RIGHTS	Issued	Allowed	Pending
US	4	0	11
Rest of World (ROW)	16	0	13

Continue to strengthen and broaden patent protection globally. Progress over the last year imparts important rights on existing products and technologies and will enable future pipeline products

Source: MRG

Investment Highlights

Effectively Executing a "Neck Up" Interventional Strategy

- 2016 return to revenue growth driven by the full launch of carotid platform through strategic distribution partnerships, including with Penumbra, Inc.
- Operating and financial realignment inline with development and growth initiatives.
- Advancing into highly valued Neuro and Peripheral markets to leverage MicroNet technology into high growth segments.
- Pursuing collaboration activities on multiple MicroNet technology applications.

Alan Milinazzo, CEO
(888) 776-6804
alanm@inspiremd.com

Craig Shore, CFO
(888) 776-6804
craigs@inspiremd.com